THERAPY DOSSIER · th-5813f483ef6b

MDP (Deinococcus Mn2+-decapeptide complex Mn-DEHGTAVMLK-Pi)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27500529 ↗2016Reported benefit

MDP: A Deinococcus Mn2+-Decapeptide Complex Protects Mice from Ionizing Radiation

MouseRadiationB6D2F1/JFemalen = 16 per groupSubcutaneous and oral300 mg DP1/kgPre-exposure (day -1 and 14 h before irradiation) and immediately post-irradiat…

Model: Whole-body gamma irradiation 9.5 Gy (LD70/30)

All 16 MDP-treated irradiated mice survived versus 63 percent lethality in vehicle-treated irradiated mice at 9.5 Gy; reduced morbidity, prevented bone marrow depletion and adipogenesis, preserved CD34 expression, ameliorated leukocytopenia, erythrocytopenia and splenomegaly, and upregulated G-CSF…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…